Skip to content

Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients

Changes in Antibacterial Therapy Based on Perioperative Dynamics of Presepsin During Reconstructive Thoracic Aorta Surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06336213
Enrollment
50
Registered
2024-03-28
Start date
2024-01-23
Completion date
2027-02-15
Last updated
2026-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Aneurysm and Dissection, Cardiac Valve Disease, Thoracic Aortic Aneurysm, Thoracic Aortic Dissection

Keywords

biomarkers, presepsin, complications, aortic arch, aorta, aortic aneurysm, ascending aorta, cardiac surgery

Brief summary

According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.

Detailed description

Various biomarkers are being used to improve the quality of prediction models aiming to improve clinical outcomes and reduce mortality in the cardiac surgery patient population. In particular, presepsin and procalcitonin have comparable prognostic value for adverse renal, cardiovascular and respiratory outcomes in cardiac surgery patients. In addition, presepsin has in-hospital, 30-day, and 6-month prognostic mortality rate value and is also highly effective for the early diagnosis of sepsis in patients in the intensive care unit. In the previous study the absence of an increase in the level of presepsin in the first 6 hours after surgery was associated with an increased risk of developing a complicated course of the postoperative period (OR 4.15, 95% CI: 1.83-9.41). The combination of two risk factors - a presepsin level at the end of surgery \>519.5 pg/ml and the absence of an increase in the presepsin level in the first 6 hours after surgery was associated with an increased risk of developing a complicated course of the postoperative period (OR 5.80, 95% CI: 2. 19-15.35). The hypothesis of this study suggests that in case of insufficient prevention of infectious complications, based on the dynamics of presepsin, it is permissible to administer the broad-spectrum drug ampicillin/sulbactam 3 g. every 6 hours for at least 72 hours from the date of surgery. It is expected that changes in the tactics of antibacterial therapy will reduce the number of inflammatory complications in patients undergoing surgery on thoracic aorta.

Interventions

If a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.

Sponsors

Petrovsky National Research Centre of Surgery
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Thoracic aorta aneurysm/dissection

Exclusion criteria

Blood sample hemolysis

Design outcomes

Primary

MeasureTime frameDescription
Infectious complications rateup to 10 daysPostoperative pneumonia, sepsis, wound infection, mediastinitis

Secondary

MeasureTime frameDescription
Total amount of complicated patientsup to 10 daysPatients that suffer at least 1 complication in postoperative period
Mortalityup to 10 daysIn-hospital mortality rate
Length of hospital stayup to 10 daysDays spent in hospital since admission
Length of ICU stayup to 10 daysHours in ICU after the surgery
Multiorgan failureup to 10 days2 or more organ dysfunction in postoperative period

Countries

Russia

Contacts

CONTACTArtem Gubko, Ph.D.
gubko@artvig.ru+79684241490
CONTACTBoris Akselrod, Professor
aksel@mail.ru+79257403797
PRINCIPAL_INVESTIGATORBoris Akselrod, Professor

Petrovsky NRCS

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026